Pauls Matthew 4/A

What Happened

• Pauls Matthew, a director of Pelthos Therapeutics Inc. (PTHS), was granted 25,478 restricted stock units (RSUs) on July 2, 2025. The grant is reported as an acquisition (code A) at $0.00 per share (total reported value $0) because RSUs represent future stock settlement rather than an immediate cash purchase.
• This Form 4 is an amendment to the original filing — the amendment reports the RSU grant in Table I (the original Form 4 reported the grant in Table II).

Key Details

• Transaction date: July 2, 2025; Amendment filed with the SEC on April 1, 2026.
• Grant: 25,478 RSUs; reported acquisition price: $0.00 per share (RSUs settle in shares upon vesting).
• Shares owned after transaction: not specified in the amended filing.
• Footnotes: (1) Each RSU represents the right to one share of Pelthos common stock and may be settled solely in shares. (2) Vesting: one-third vested on July 2, 2025; the remaining two-thirds vest in equal quarterly installments over the next two years, subject to continued service as a director.
• Remarks: Exhibit 24 (Power of Attorney) is included with the filing.
• Filing status: This is an amended Form 4 filed in 2026 to adjust how the original grant was reported; review the original Form 4 for initial timing details.

Context

• RSU grants are a common form of director compensation and do not represent an open-market purchase or sale. They convey potential future ownership if the director remains in service and the RSUs vest; they are not immediate cash compensation.